Literature DB >> 8228340

Differential mortality by measles vaccine titer and sex.

E A Holt1, L H Moulton, G K Siberry, N A Halsey.   

Abstract

Mortality was evaluated in 1972 children who had received measles vaccines at 6-11 months of age that were 10-fold (medium titer) or 100-fold (high titer) greater than standard titer. Mortality among boys did not differ by vaccine titer and was similar to mortality in children who received standard-titer vaccine. Girl recipients of high-titer vaccine had somewhat greater mortality than girls who received medium-titer vaccine (risk ratio = 1.71, 95% confidence interval = 0.91-3.24). Increased mortality was associated with high-titer vaccine for girls but not for boys (P = .04). There was no evidence of selection bias or preferential health care by sex that might explain the differential mortality. This mortality pattern has been noted in two other populations with high background infant and childhood mortality. The biologic basis for this effect on mortality has not been determined. Data from this and other studies have resulted in discontinuation of the use of high-titer measles vaccines.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8228340     DOI: 10.1093/infdis/168.5.1087

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  23 in total

1.  Non-specific beneficial effect of measles immunisation: analysis of mortality studies from developing countries.

Authors:  P Aaby; B Samb; F Simondon; A M Seck; K Knudsen; H Whittle
Journal:  BMJ       Date:  1995-08-19

2.  Sex-associated differences in the antibody-dependent cellular cytotoxicity antibody response to measles vaccines.

Authors:  S Atabani; G Landucci; M W Steward; H Whittle; J G Tilles; D N Forthal
Journal:  Clin Diagn Lab Immunol       Date:  2000-01

Review 3.  Measles Vaccine.

Authors:  Diane E Griffin
Journal:  Viral Immunol       Date:  2017-12-19       Impact factor: 2.257

4.  Generation of a More Immunogenic Measles Vaccine by Increasing Its Hemagglutinin Expression.

Authors:  Emily Julik; Jorge Reyes-Del Valle
Journal:  J Virol       Date:  2016-05-12       Impact factor: 5.103

5.  Bacterial lysates improve the protective antibody response against respiratory viruses through Toll-like receptor 4.

Authors:  Silvina Coviello; Vera Wimmenauer; Fernando P Polack; Pablo M Irusta
Journal:  Hum Vaccin Immunother       Date:  2014-11-19       Impact factor: 3.452

6.  Functional and phenotypic changes in circulating lymphocytes from hospitalized zambian children with measles.

Authors:  Judith J Ryon; William J Moss; Mwaka Monze; Diane E Griffin
Journal:  Clin Diagn Lab Immunol       Date:  2002-09

7.  Dose-dependent protection against or exacerbation of disease by a polylactide glycolide microparticle-adsorbed, alphavirus-based measles virus DNA vaccine in rhesus macaques.

Authors:  Chien-Hsiung Pan; Nitya Nair; Robert J Adams; M Christine Zink; Eun-Young Lee; Fernando P Polack; Manmohan Singh; Derek T O'Hagan; Diane E Griffin
Journal:  Clin Vaccine Immunol       Date:  2008-02-20

8.  Comparison of the immune responses induced by chimeric alphavirus-vectored and formalin-inactivated alum-precipitated measles vaccines in mice.

Authors:  M Jeff Bergen; Chien-Hsiung Pan; Catherine E Greer; Harold S Legg; John M Polo; Diane E Griffin
Journal:  PLoS One       Date:  2010-04-22       Impact factor: 3.240

9.  Non-specific effects of standard measles vaccine at 4.5 and 9 months of age on childhood mortality: randomised controlled trial.

Authors:  Peter Aaby; Cesário L Martins; May-Lill Garly; Carlito Balé; Andreas Andersen; Amabelia Rodrigues; Henrik Ravn; Ida M Lisse; Christine S Benn; Hilton C Whittle
Journal:  BMJ       Date:  2010-11-30

10.  Differential immune responses to primary measles-mumps-rubella vaccination in Israeli children.

Authors:  Bracha Rager-Zisman; Elina Bazarsky; Agneta Skibin; Guy Tam; Shlomo Chamney; Ilana Belmaker; Iris Shai; Ella Kordysh; Diane E Griffin
Journal:  Clin Diagn Lab Immunol       Date:  2004-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.